We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

49 hedge funds and large institutions have $454M invested in Keros Therapeutics in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

11% more capital invested

Capital invested by funds: $410M → $454M (+$44.5M)

4.18% more ownership

Funds ownership: 54.22% → 58.41% (+4.2%)

4% less funds holding

Funds holding: 51 → 49 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
0.99%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
6
Increased
17
Reduced
15
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$47.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17M
3
FI
Fosun International
China
+$3.31M
4
AS
Altshuler Shaham
Israel
+$1.01M
5
Goldman Sachs
Goldman Sachs
New York
+$703K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$11.3M
2
EC
EcoR1 Capital
California
-$8.26M
3
Citadel Advisors
Citadel Advisors
Florida
-$5.9M
4
Invesco
Invesco
Georgia
-$4.51M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$72.3M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$69M +$17M +428,873 +32%
O
3
OrbiMed
New York
$64.8M – – –
LGM
4
Logos Global Management
California
$61.7M +$47.6M +1,200,000 +300%
FCMI
5
Foresite Capital Management IV
California
$54.5M -$609K -15,366 -1%
VA
6
VR Adviser
New York
$25.9M – – –
BlackRock
7
BlackRock
New York
$25.2M -$225K -5,679 -0.9%
CA
8
CHI Advisors
New York
$22M -$408K -10,286 -2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$11.5M -$534K -13,476 -4%
NCM
10
Nantahala Capital Management
Connecticut
$10.7M +$72.5K +1,827 +0.7%
Invesco
11
Invesco
Georgia
$7.25M -$4.51M -113,743 -38%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$4.24M +$111K +2,800 +3%
State Street
13
State Street
Massachusetts
$3.83M +$564K +14,215 +17%
FI
14
Fosun International
China
$3.22M +$3.31M +83,545 New
Northern Trust
15
Northern Trust
Illinois
$3.21M -$171K -4,309 -5%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$3.12M -$2.84M -71,500 -47%
Charles Schwab
17
Charles Schwab
California
$1.69M +$17.5K +442 +1%
Alkeon Capital Management
18
Alkeon Capital Management
New York
$1.16M – – –
N
19
Nuveen
North Carolina
$1.04M +$4.52K +114 +0.4%
AS
20
Altshuler Shaham
Israel
$985K +$1.01M +25,546 New
TC
21
Telemus Capital
Michigan
$775K +$198K +5,000 +50%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$699K -$3.37K -85 -0.5%
Renaissance Technologies
23
Renaissance Technologies
New York
$683K +$452K +11,400 +181%
Goldman Sachs
24
Goldman Sachs
New York
$683K +$703K +17,718 New
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$618K +$23.8K +600 +4%
1
2 3

KROS Hedge Fund Activity: Q3 2020 in Review

49 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2020, worth a combined $454M — up 11% from $410M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of KROS and 6 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 17 added.

The largest buyer was Logos Global Management, adding an estimated $47.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $11.3M sold.

  • 49 institutional investors held Keros Therapeutics (KROS) as of Q3 2020, down from 51 in Q2 2020.
  • Funds reported $454M of Keros Therapeutics stock for Q3 2020, up 11% quarter-over-quarter.
  • 6 funds opened new Keros Therapeutics positions in Q3 2020 and 8 closed out, a net change of -2 holders.
  • The largest Keros Therapeutics buyer in Q3 2020 was Logos Global Management, an estimated $47.6M added.
  • The largest Keros Therapeutics seller in Q3 2020 was Deerfield Management, an estimated $11.3M sold.

Based on aggregated 13F filings for Q3 2020.